Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1303 DARTS: radiotherapy alone versus radiotherapy plus temozolomide for unresectable grade II diffuse astrocytoma
jRCTs031180201Phase 3Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in diffuse astrocytoma (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Sep 2014; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
diffuse astrocytoma
Beyond the preview
Go deeper on jRCTs031180201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180201.